Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors

Next Previous
X
Search
Trial Profile

First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 002 (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Neuroblastoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms AMPLIFY-201; The novel study
  • Sponsors Elicio Therapeutics

    • Most Recent Events

    • 13 Aug 2024 According to Elicio Therapeutics media release, long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings.
    • 16 May 2024 According to Elicio Therapeutics media release, company Provided updated immunogenicity and relapse-free survival data in the fourth quarter of 2024
    • 06 Mar 2024 According to a Natera Media Release, today announced poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024, in San Diego, California. The presentations will highlight data on Elicio's therapeutic cancer vaccine candidates, ELI-002, ELI-007 and ELI-008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top